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Abstract
We report results of a nonsynonymous SNP scan for ulcerative colitis and identify a previously
unknown susceptibility locus at ECM1. We also show that several risk loci are common to
ulcerative colitis and Crohn’s disease (IL23R, IL12B, HLA, NKX2-3 and MST1), whereas
autophagy genes ATG16L1 and IRGM, along with NOD2 (also known as CARD15), are specific
for Crohn’s disease. These data provide the first detailed illustration of the genetic relationship
between these common inflammatory bowel diseases.
Ulcerative colitis and Crohn’s disease are debilitating inflammatory bowel diseases (IBDs)
affecting 1 in 250 individuals of Northern European ancestry. Genetic epidemiological data
suggest that they share some but not all susceptibility loci. NOD2, identified in 2001, is
specific to Crohn’s disease. Recently, we and others used genome-wide association scans
(GWAS) to identify at least ten more loci confirmed to be associated with risk of Crohn’s
disease (reviewed in ref. 1).
We now present the first nonsynonymous SNP (nsSNP) scan in ulcerative colitis. We used a
staged experimental design. Our discovery cohort of 905 ulcerative colitis cases and 1,465
controls (panel 1) were genotyped using an array custom-made for the Welcome Trust Case
Control Consortium (WTCCC; Supplementary Methods online)2. After removing poorly
performing samples and markers, we analyzed 10,886 nsSNPs and MHC tag SNPs
(Supplementary Methods and Supplementary Figs. 1-3 online). We found 33 markers
from 21 distinct loci associated at P < 0.001. These were then genotyped in another 936
ulcerative colitis cases and 1,470 control subjects (panel 2; statistics on all cases and
controls summarized in Supplementary Table 1 online). Five SNPs from three loci replicated
(Table 1 and Supplementary Table 2 online). Finally, we tested 16 SNPs tagging 13 known
Crohn’s disease-associated loci for association with ulcerative colitis (Table 2 and
Supplementary Table 3 online)1.
Of loci not previously associated with IBD, the strongest association in panel 1 was at two
nsSNPs in ECM1 on chromosome 1q21.2 (P = 1.3 × 10−4 at rs3737240; P = 2.6 × 10−4 at
rs13294). As this was the strongest new signal, we genotyped these markers in panel 2 and
in another independent cohort of 1,146 cases and 1,559 controls (panel 3), and we observed
support for the association in both (Table 1). After combining all three panels (2,987 cases
and 4,494 controls), association at rs3737240 was significant at P = 2.3 × 10−6 and rs13294
at P = 7.9 × 10−6. The result at rs3737240 withstands Bonferroni correction for 10,886
markers (threshold for significance P < 4 × 10−6) and meets suggested significance levels of
P < 10−4 to P < 10−6 for gene-centric studies2,3. Association at ECM1 may be specific to
ulcerative colitis, as this region was not associated with Crohn’s disease in the WTCCC
scan4.
The ECM1 locus, delimited by recombination hotspots, spans 290 kb and includes MRPS21,
PRPF3 and TARS2. nsSNPs in flanking blocks showed no association. In additional
mapping experiments, we genotyped seven SNPs that fully tag ECM1 in 1,841 cases (from
panels 1 and 2) and 1,470 controls (panel 2), with rs11205387 and rs11810419 showing
association with ulcerative colitis (Supplementary Table 4 online). Conditional regression
analysis showed that neither nsSNP in ECM1 fully explained the association. Fine mapping
will identify whether the causal variant maps within ECM1 or elsewhere in this haplotype
Fisher et al. Page 2
Nat Genet. Author manuscript; available in PMC 2009 July 31.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
block. However, ECM1 is a plausible candidate gene for ulcerative colitis: it encodes
extracellular matrix protein 1, a glycoprotein expressed in small and large intestine, and it
interacts with the basement membrane and inhibits matrix metalloproteinase 9 (ref. 5).
Notably, ECM1 strongly activates NF-κB signaling6, a key immune regulator. Expression is
upregulated in colorectal cancer and metastases, implicating ECM1 in epithelial-stromal
interaction5. rs3737240 and rs13294 encode substitutions T130M and G290S: Thr130,
residing within a collagen IV binding domain, is conserved in primates and pigs but not
rodents, whereas Gly290 is not conserved. Of note, the WTCCC observed modest
association between these ECM1 SNPs and ankylosing spondylitis, a related inflammatory
disorder (P = 0.0041 and 0.0044, respectively)4.
Replicating earlier findings7, multiple MHC markers showed strong association with
ulcerative colitis in panel 1 (Supplementary Fig. 4 online). Association peaked around
rs6927022 (P = 4.7 × 10−8) in a 400-kb haplotype block containing BTNL2 and the HLA
loci HLA-DQA1, HLA-DRA, HLA-DRB5 and HLA-DRB1, and was independently
replicated (Table 1; rs6927022 could not be genotyped in panel 2 for technical reasons).
Previous reports confirmed association between HLA-DRB1 and ulcerative colitis7,8 but
did not resolve whether the causal variant lay within this or a neighboring haplotype block.
Our high marker density and large panel size successfully resolved this issue: distal to the
recombination hotspots, association diminished substantially, indicating that the causal
variant does indeed map to this block.
Resolving the causal variant within this block is hindered by tight linkage disequilibrium
(LD). Association between BTNL2 variants and ulcerative colitis in Japanese populations
was explained by LD with HLA-DRB1*1502 (ref. 9). We stratified BTNL2 genotypes by
DRB1*1502 status: clear residual association with BTNL2 (P = 0.0036 at rs9268480)
suggests contribution of this gene or another in LD with it. DRB1*0103 was previously
associated with ulcerative colitis, especially severe disease7,8. Whether this rare allele
accounts for the signal we observed awaits formal HLA genotyping.
To clarify genetic correlations between ulcerative colitis and Crohn’s disease, we partitioned
WTCCC Crohn’s disease cases into colonic-only (n = 501) and ileal-only (n = 534)
subphenotypes, and implemented a ‘within-cases’ test of association on the GWAS data
(Supplementary Methods). We found that multiple HLA markers within the 400-kb block
identified in our ulcerative colitis scan were significantly associated with colonic Crohn’s
disease, peaking at rs3129872 (P = 6.8 × 10−9, HLA-DRA). This corroborates previous
association between HLA-DRB1*0103 and colonic Crohn’s disease10 and refines the signal
to this haplotype block. Compared to healthy controls (MAF = 0.292), the allele frequency
at rs3129872 was significantly elevated in colonic Crohn’s disease cases (P = 4.8 × 10−4,
MAF = 0.347) and reduced in ileal cases (P = 5.18 × 10−5, MAF = 0.231). We nominally
replicated this association (P = 9.7 × 10−3) in our smaller Crohn’s disease replication cohort
(Supplementary Table 5 online). Thus, determinants within this haplotype block both
increase risk of ulcerative colitis and colon-only Crohn’s disease and decrease risk of small
bowel Crohn’s disease. This suggests shared pathogenic mechanisms for colonic forms of
IBD distinct from small bowel inflammation.
The third replicable locus detected in the nsSNP scan was MST1 on chromosome 3p21, a
region also associated with Crohn’s disease4,11. nsSNP rs3197999 (Ppanel 1+2 = 6.0 × 10−6;
Table 1) results in amino acid change R689C. We subsequently genotyped 20 SNPs tagging
the MST1 locus and seven nsSNPs from surrounding genes with MAF > 0.02, capturing (r2
> 0.8) 70/73 Hapmap SNPs from the 193-kb haplotype block encompassing this locus and
86/93 and 122/136 HapMap SNPs from the 301-kb and 279-kb flanking blocks,
respectively. Association peaked at MST1 (Supplementary Table 4). Conditional regression
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analysis showed a marginally significant haplotype effect with rs34823813 and rs9853352.
The latter two SNPs in RNF123 and IHPK1 are within the same haplotype block as MST1
and are in strong LD (r2 = 0.95). Although their contribution to ulcerative colitis risk cannot
be excluded, the evidence more strongly implicates nsSNP rs3197999 as causal or in strong
LD with the causal variant at this locus. Arg689 is strongly conserved in mammals, and
MST1 is known to suppress cell-mediated immunity by down-regulating IL-12 (ref. 12).
Finally, we genotyped 16 SNPs tagging 13 Crohn’s disease-associated loci identified by
GWAS1 in 1,841 ulcerative colitis cases (panels 1 and 2) and 1,470 controls (panel 2).
Previous smaller studies, including our own using a panel partially overlapping with the
current dataset (Supplementary Methods), had identified modest association between
ulcerative colitis and IL23R variants13,14. Here this association was confirmed (P = 1.3 ×
10−5 at rs11805303) (Table 2 and Supplementary Table 3) and refined by genotyping five
additional IL23R SNPs. In contrast to earlier reports13,14, in ulcerative colitis, but
consistent with findings in Crohn’s disease14, conditional regression analysis in our large
ulcerative colitis panel demonstrated that rs11209026 (R381G) provided the strongest signal
(P = 8.9 × 10−8, OR = 0.53), with evidence that additional independent variants also
contribute to ulcerative colitis risk (Supplementary Table 4). Association was also observed
at rs6556416 in IL12B (P = 6.8 × 10−4), which encodes a subunit shared by IL-12 and IL-23
(Table 2). Thus, the Th17 pathway seems as relevant to ulcerative colitis as to Crohn’s
disease13,14, ankylosing spondylitis2 and psoriasis15.
Among other Crohn’s disease-associated loci, association with ulcerative colitis was also
seen for the transcription factor gene NKX2-3 (for rs10883365, P = 3.3 × 10−4 in the
ulcerative colitis panel and P = 2.4 × 10−6 using the expanded WTCCC control panel; Table
2). Thus, NKX2-3 represents another generic IBD locus. However, no association with
ulcerative colitis was seen at IRGM (P = 0.72), PTPN2 (P = 0.17), ATG16L1 (P = 0.11) or
the chromosome 5p13 gene desert (P = 0.19), despite 80% power to detect an allelic OR =
1.15 with MAF = 0.17 at P = 0.05 (PTPN2 effect in Crohn’s disease) and >95% power for
OR = 1.36 with MAF = 0.12 at P = 0.0001 (comparable to IRGM and ATG16L1 in Crohn’s
disease).
Several Crohn’s disease-associated loci, including the MST1 locus and variants in the IL-23
pathway, evidently also contribute to ulcerative colitis susceptibility. However, some are
disease-specific. Notably, genes associated with Crohn’s disease but not ulcerative colitis,
including NOD2 and autophagy genes ATG16L1 and IRGM, affect intracellular handling of
bacterial antigens, suggesting distinct pathogenic mechanisms relating to microbial
processing. Additional susceptibility loci have yet to be identified, and the scene is set for
GWA scans for ulcerative colitis. However, in identifying a previously unknown ulcerative
colitis–associated locus at ECM1 and defining the extent of its overlap with Crohn’s
disease-associated loci, we have made substantial progress both in understanding the key
pathogenic pathways for ulcerative colitis and in illuminating the genetic relationship
between these two forms of inflammatory bowel disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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